Table 5.

Health-related quality of life in Crohn’s disease patients treated with ustekinumab

	Baseline Median (IQR)	Week 16 Median (IQR); p-value	Week 52 Median (IQR); p-value	Week 104 Median (IQR); p-value
SHS	n = 105/114	n = 93/105	n = 69/80	n = 52/69
Bowel symptoms	2 (2–3)	2 (1–2); < .001	1 (1–2); < .001	1 (0–1); < .001
Activities of daily living	2 (2–3)	1 (1–2); < .001	1 (0–2); < .001	1 (0–1); < .001
Worry	2 (2–3)	2 (1–2); < .001	1 (1–2); < .001	1 (1–1); < .001
General wellbeing	2 (2–3)	2 (1–2); < .001	2 (1–2); < .001	1 (1–2); < .001
Sum SHS	9 (7–12)	6 (4–9); < .001	5 (3–8); < .001	4 (2–5); < .001
EQ-5D-5L	n = 103/114	n = 89/105	n = 69/80	n = 54/69
Mobility	1 (1–1)	1 (1–1); .88	1 (1–1); .69	1 (1–1); .31
Self-care	1 (1–1)	1 (1–1); .14	1 (1–1); .41	1 (1–1); .08
Usual activities	1 (1–3)	1 (1–2); .03	1 (1–2); .01	1 (1–1) < 0.001
Pain/discomfort	3 (2–3)	2 (1–3); < .001	2 (1–3); < .001	1 (1–2) < 0.001
Anxiety/depression	2 (1–3)	2 (1–2); .21	2 (1–2); .04	2 (1–2); .23
Visual analogue scale	70 (45–80)	75 (65–80); < .001	80 (70–90); < .001	85 (80–90); < .001
EQ-5D-5L index value	0.86 (0.77–0.92)	0.91 (0.83–0.94); < .001	0.91 (0.86–0.97); < .001	0.97 (0.91–1); < .001

EQ-5D-5L = EuroQual 5-Dimensions, 5-Levels; IQR = interquartile range; SHS = Short Health Scale

Median and p-values at weeks 16, 52 and 104 compared to baseline